Drug Profile

VX A903 2

Alternative Names: VX-A903-2

Latest Information Update: 31 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VERAXA Biotech
Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

17 Oct 2025 VX A903 2 is available for licensing as of 17 Oct 2025. https://www.veraxa.com/partnering
10 Oct 2025 Early research in Lung cancer in Germany (Parenteral) (VERAXA Biotech pipeline, October 2025)
10 Oct 2025 Early research in Pancreatic cancer in Germany (Parenteral) (VERAXA Biotech pipeline, October 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com